Lanean...
Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition
Vascular endothelial growth factor (VEGF) has emerged as a therapeutic target in several malignancies, including cervical cancer. Chemotherapy doublets combined with the fully humanized monoclonal antibody, bevacizumab, now constitute first-line therapy for women struggling with recurrent/metastatic...
Gorde:
| Argitaratua izan da: | Gynecol Oncol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6720107/ https://ncbi.nlm.nih.gov/pubmed/29666026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.01.009 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|